Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-31
2005-05-31
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S033000, C514S089000, C514S177000, C514S178000, C549S289000, C424S649000
Reexamination Certificate
active
06900239
ABSTRACT:
A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.
REFERENCES:
patent: 6020363 (2000-02-01), Hirano et al.
Stein, J. H., Editor-in-Chief, Internal Medicine, Fourth Edition, Chapters 71 and 72, 1994.*
DiPiro, J. T., Editor-in-Chief, Pharmacotherapy, A Pathophysiologic Approach, pp. 1354, 1355, and p. 1496, 1989.*
Teicher et al., “Optimal Scheduling of Interleukin-12 and Fractionated Radiation Therapy in the Murine Lewis Lung Carcinoma,” Radiation Oncology Investigations, 6:71-80, 1998.
Kawai et al., Enhancement of Anticancer Effects of Radiation and Conventional Anticancer Agents by a Quniolinone derivative, Vesnarinone: Studies on Human Gastric Cancer Tissues in Nude Mice, Anticancer Res., 18:405-412, 1998.
Voest et al., “Inhibition of Angiogenesis In Vivo by Interleukin 12,” J. Nat'l Cancer Inst., 87:581-586, 1995.
Gorski et al., Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation, Cancer Res., 59:3374-3378, 1999.
Norioka et al., Interaction of Interleukin-1 and Interferon-g on Fibroblast Growth Factor-Induced Angiogenesis, Jpn. J. cancer Res., 85:522-529, 1994.
Mauceri et al., “Combined effects of Angiostatin and Ionizing Radiation in Antitumor Therapy,” Nature, 394:287-291, 1998.
Matsumoto et al. “Synthesis and Biological Evaluation of Cytogenin Derivatives,” J. Antibiotics, 54:285-296, 2001.
Salloum et al., NM-3, an Isocoumarin, Increases the Antitumor Effect of radiotherapy without Toxicity, Cancer Res., 60:6958-6963, 2000.
Agata et al., NM-3, a Novel Angiogenesis Inhibitor, Potentiates Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells, Proceedings of the 2001 AACR-NCI-EORTC International Conference, p67 Oct. 2001.
Yin et al., “The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) Propionic Acid (NM-3) Induces lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species,” Mol. cancer Therapeutics, 1:43-48, 2001.
Reimer et al., “Antineoplastic Effects of Chemotherapeutic Agents are Potentiated by NM-3, an Inhibitor of Angiogenesis,” Cancer Res., 62:789-795, 2002.
Nakashima, et al., “Inhibition of Angiogenesis by a New Isocoumarin NM-3,” J. Antibiotics, 52:426-428, 1999.
Kumagi, et al., “Antitumor Activity of Cytogenin,” J. Antibiotics, 48:175-178, 1995.
Oikawa, et al., “Effects of Cytogenin, a Novel Microbial Product, on Embryonic and Tumor Cell-Induced Angiogenic Responses In Vivo,” Anticancer Res., 17:1881-1889, 1997.
Agata Naoki
Kharbanda Surender
ILWZ ILEX Products, Inc.
Jecminek Al A.
Jones Dwayne
Moloney Stephen J.
LandOfFree
Tumor chemopotentiation using isocoumarin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor chemopotentiation using isocoumarin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor chemopotentiation using isocoumarin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463658